Global law firm White & Case LLP has advised Carnegie, DNB Markets, J.P. Morgan, Cowen and Kempen & Co, as joint bookrunners, on the SEK 1.106 billion (approximately US$130 million) directed share issue by Oncopeptides.
The Oncopeptides board of directors resolved on the directed issue of seven million shares at a subscription price of SEK 158 per share, with the company receiving gross proceeds of SEK 1.106 billion (approximately US$130 million). The subscription price was determined through an accelerated bookbuild procedure.
Established in 2000 and based in Stockholm, Sweden Oncopeptides is a pharmaceutical company that develops drugs for the treatment of cancer
The White & Case which advised on the transaction was led by partners Rikard Stenberg (Stockholm) and Mikko Hulkko (Helsinki) and included associates Christoffer Nilmén (Stockholm) and Benjamin Tuiskula (Helsinki).
For more information please speak to your local media contact.